Antibacterial Agents TRIZ Cases

A peptide composition detaches single cell organisms from surfaces by disrupting biofilm clusters.

Lactobacillus species restore the natural skin barrier by stimulating beneficial flora and competing with pathogenic colonization.

Recombinant QC1 and QC2 proteins enable selective inhibitor screening against glutaminyl cyclase isoenzymes.

Engineered polypeptides resolve stability and broad-spectrum activity trade-offs via parameter changes.

Selective class II HDAC inhibition reduces adverse effects from non-specific inhibitors while maintaining therapeutic efficacy.

Conjugating monobactams with bis-catechol siderophores targets carbapenemase-producing Acinetobacter baumannii strains.

Bacteriophage Aer-HYP-3 selectively destroys Aeromonas hydrophila pathogens while preserving normal microflora balance in fish farming.

Anti-CD39 antibodies target CD39 enzymes on Treg cells to reduce adenosine levels, restoring anti-tumor and anti-viral immune responses.

Alkynyl derivatives with specific ring structures inhibit DPP-1, addressing inadequate treatment of COPD and asthma by modulating proteolytic imbalances.

Cyclic peptides inhibit the Bam complex, disrupting outer membrane integrity and overcoming intrinsic resistance in Gram-negative bacteria.

Chimeric nucleases create double-stranded breaks to enhance gene targeting efficiency, resolving low modification rates at non-homologous sites.

A PTX3-Fc fusion protein combines the N-terminal domain of pentraxin 3 with an immunoglobulin Fc portion to create a stable therapeutic agent.

Erythrocyte-derived vesicles replace synthetic nanomaterials to resolve insufficient cellular immunity and toxic side effects in immunotherapy.

Arylpyrazole ethers block leukotriene production by inhibiting LTA4H, addressing the lack of effective inhibitors for asthma and cardiovascular diseases.

Inhibiting factor XII activity prevents arterial and venous thrombi formation through the intrinsic coagulation pathway.

2,4-diaminopyrimidine derivatives inhibit FAK/PTK2 to induce apoptotic cell death, resolving the trade-off between kinase specificity and anti-tumor efficacy.

Tricyclic atropisomer compounds form covalent bonds with Bruton's tyrosine kinase to achieve irreversible enzyme inhibition.

Stable neoglycoconjugates resolve the contradiction between vaccine reliability and composition stability by using defined linkers.

A pH-sensitive cationic lipid with pKa 3.5 to 8 resolves serum aggregation and cytotoxicity while enabling stable encapsulation.

A silver hyaluronic acid wound dressing stimulates fibroblast proliferation and migration.

Targeting upstream NLRP3 activation with specific sulfonylureas eliminates residual disease and immunosuppression caused by downstream IL-1 blockade.

A Smad3-based fusion protein delivers targeted immunomodulation to treat autoimmune conditions.

A lipid-saturated polymer matrix provides sustained release of active pharmaceutical ingredients.

Threoglucins inhibit Streptococcus suis growth at low concentrations while sparing human cells and beneficial bacteria from toxicity.

Delphinidin-enriched anthocyanidin compositions stimulate immune function and reduce inflammation through synergistic antioxidant activity.

Bromelain-based oral formulation prevents bacterial attachment to the gut lining, treating diarrhea while avoiding antibiotic resistance proliferation.

N-chlorinated heterocyclic structures resolve mammalian cell toxicity trade-offs while maintaining broad-spectrum antimicrobial efficacy.

Size fractionation isolates distinct antibody fractions from human immunoglobulin preparations.

N,N-dihaloamino acid compounds convert unstable hypochlorous acid into stable derivatives, reducing cytotoxicity and improving storage reliability.

Administering HDAC and GRK2 inhibitors rescues impaired neutrophil function suppressed by systemic inflammatory response syndrome.

Chromatography isolates deshydroxy vancomycin from fermentation broth, resolving the trade-off between structural novelty and antibacterial reliability.

APIM peptides bind microbial PCNA proteins to disrupt DNA replication, overcoming multidrug-resistant bacterial strains that evade traditional antibiotics.

A cationic peptide-polymer composite reduces ion flow into excitable cells to modulate nerve activity.

Water-insoluble meropenem derivatives form mucus-penetrating particles to extend local lung exposure and reduce systemic clearance.

Novel CGRP antagonists with specific chemical formulas offer selective receptor binding to treat migraines while reducing side effects.

New cephem compounds feature a bicyclic nitrogen-containing aromatic heterocyclic ring at the 3-position to enhance antibacterial activity.

Multivalent peptide conjugates from Pf bacteriophage coat proteins stimulate protective immunity against Pseudomonas aeruginosa.

A killed vaccine formulation containing serovar type 4 DNA sequences triggers a protective immune response in pigs.

Crystalline solid forms of tigecycline enhance bioavailability by eliminating complex low-oxygen processing requirements.

Segmented layers provide burst and sustained antibiotic release to prevent systemic toxicity.

Linear peptides resist protease degradation while inhibiting Erwinia amylovora, solving production cost and stability trade-offs.

DVD binding proteins resolve molecular heterogeneity and immunogenicity trade-offs via segmented constant domains and linkers.

Cost-effective synthetic peptides replace expensive monoclonal antibodies to inhibit TcdB toxicity while maintaining broad-spectrum efficacy.

A polycationic polymer containing protonated guanidine groups attracts and destroys microbial cell membranes through electrostatic interactions.

Novel recombinant antimicrobial peptides inhibit biofilm formation and bacterial growth in resistant Staphylococcus strains.

Cashew nut shell liquid replaces synthetic antibiotics to reduce environmental pollution while improving feed efficiency through targeted microbial modulation.